Study on the clinical efficacy and TCM syndrome element changes of modified Longgu Muli Decoction in the treatment of chronic atrophic gastritis

This study, designed as a retrospective study, aims to investigate the clinical efficacy of Longgu Muli Decoction plus additions in treating chronic atrophic gastritis (CAG) and the changes in traditional Chinese medicine (TCM) syndromes. Sixty patients with CAG were enrolled and divided into the observation group and control group according to different treatment methods, with 30 patients in each group. The observation group received Longgu Muli Decoction plus additions, while the control group received conventional treatment. The treatment duration was 4 weeks. Clinical efficacy, TCM syndrome scores, gastrointestinal hormone levels, serum inflammatory factor levels, and sleep quality of the 2 groups were evaluated before and after treatment. Data were analyzed using SPSS 22.0 statistical software. The total effective rate in the observation group was 96.67%, significantly higher than 86.67% in the control group (P < .05). After treatment, the TCM syndrome scores, gastrointestinal hormone levels (endothelin [ET], calcitonin gene-related peptide [CGRP], epidermal growth factor [EGF]), and serum inflammatory factor levels (tumor necrosis factor-α [TNF-α], interleukin-6 [IL-6], C-reactive protein [CRP]) in the observation group were significantly better than those in the control group (P < .05). Moreover, the Pittsburgh Sleep Quality Index (PSQI) total score and various subscale scores in the observation group were significantly lower than those in the control group (P < .05). Longgu Muli Decoction plus additions has significant clinical efficacy in treating CAG. It can effectively improve gastrointestinal function, reduce inflammatory reactions, and enhance sleep quality, thus demonstrating high clinical application value.